Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder

Phase 3 Unknown 20 enrolled Canive, Jose M., M.D. Eli Lilly and Company · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Duloxetine (Cymbalta®) is an effective treatment in reducing the symptoms of Posttraumatic Stress Disorder (PTSD).

Timeline

Start: 2005-12
Primary completion: —
Completion: 2008-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	60 mg	—

Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder

Summary

Timeline

Drugs

Indications